Overall Technical outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Revenue projections:

Revenue projections for DGX
Investors are expected to be cautious with DGX, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.700000
forwardPE 21.677494
debtToEquity 79.654000
earningsGrowth 0.287000
revenueGrowth 0.100000
grossMargins 0.331810
operatingMargins 0.149230
trailingEps 10.040000
forwardEps 11.977860

DGX's current ratio of 1.7, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as DGX has enough cash and current assets to handle its immediate liabilities comfortably.
DGX's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
Quest Diagnostics Incorporated's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Quest Diagnostics Incorporated is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for DGX
Quest Diagnostics Incorporated's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about Quest Diagnostics Incorporated's ability to generate strong results going forward.

Insider Transactions:

Insider Transactions for DGX

17 sales transactions of Quest Diagnostics Incorporated were conducted, with market price at 209.90905492446.There were 3 buy transactions of Quest Diagnostics Incorporated stock, with market price at 196.2933349609375 per share.The insider transaction data shows no clear pattern or trend, making it difficult to draw any meaningful conclusions about the company's current direction based on this information.

Recommendation changes over time:

Recommendations trend for DGX

Quest Diagnostics Incorporated has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as Quest Diagnostics Incorporated is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.